GBIM Stock - GlobeImmune, Inc.
Unlock GoAI Insights for GBIM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|
| Revenue | $6.46M | $5.97M | $22.52M | $14.64M | $5.11M |
| Gross Profit | $3.81M | $974,169 | $13.49M | $14.63M | $5.11M |
| Gross Margin | 59.0% | 16.3% | 59.9% | 99.9% | 100.0% |
| Operating Income | $-2,766,905 | $-5,819,118 | $7.69M | $-3,966,484 | $-12,593,460 |
| Net Income | $-2,766,905 | $-20,151,588 | $9.48M | $-2,014,744 | $-14,857,235 |
| Net Margin | -42.8% | -337.8% | 42.1% | -13.8% | -290.9% |
| EPS | $-0.48 | $-6.91 | $-35.64 | $-21.07 | $-155.37 |
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
Visit WebsiteEarnings History & Surprises
GBIMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2016 | May 12, 2016 | — | $-0.15 | — | — |
Q1 2016 | Mar 16, 2016 | — | $-0.14 | — | — |
Q4 2015 | Nov 13, 2015 | — | $-0.13 | — | — |
Q3 2015 | Aug 14, 2015 | — | $-0.23 | — | — |
Q2 2015 | May 14, 2015 | — | $-0.27 | — | — |
Q4 2014 | Dec 31, 2014 | — | $-0.30 | — | — |
Q4 2014 | Nov 12, 2014 | — | $-0.64 | — | — |
Q2 2014 | Jun 30, 2014 | — | $-1.04 | — | — |
Q1 2014 | Mar 31, 2014 | — | $-0.44 | — | — |
Q4 2013 | Dec 31, 2013 | — | $108.64 | — | — |
Q3 2013 | Sep 30, 2013 | — | $-7.20 | — | — |
Q2 2013 | Jun 30, 2013 | — | $11.69 | — | — |
Q1 2013 | Mar 31, 2013 | — | $-15.82 | — | — |
Q2 2012 | Jun 30, 2012 | — | $-10.50 | — | — |
Q1 2012 | Mar 31, 2012 | — | $-22.95 | — | — |
Q2 2011 | Jun 30, 2011 | — | $-33.23 | — | — |
Q1 2011 | Mar 31, 2011 | — | $-32.47 | — | — |
Latest News
Frequently Asked Questions about GBIM
What is GBIM's current stock price?
What is the analyst price target for GBIM?
What sector is GlobeImmune, Inc. in?
What is GBIM's market cap?
Does GBIM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GBIM for comparison